Sun Pharma gets USFDA nod for generic Mesalamine Extended Release Capsules; Stock climbs 2.5%

13 May 2022 , 10:41 AM

Sun Pharmaceutical Industries Limited has announced that it has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Mesalamine Extended Release Capsules, 500 mg.

The generic product approval is based on Pentasa Extended Release Capsules, 500mg as a reference product.

As per March 2022 IQVIA Health data, Pentasa Extended Release Capsules, 500mg had annualized sales of approximately US$ 213 million in USA.

On Friday at around 10:44 AM, Sun Pharmaceuticals was trading at Rs871.10 apiece up by Rs20.95 or 2.46% from its previous closing of Rs850.15 apiece on the BSE.